Don't Rush to Prescribe Olumiant or Xeljanz XR for Rheumatoid Arthritis
December 2018
Olumiant (baricitinib) and Xeljanz XR (tofacitinib) will be new once-daily oral meds for rheumatoid arthritis (RA).
Olumiant (oh-LOO-mee-ant) is the second Janus kinase (JAK) inhibitor for RA on the market after Xeljanz.
And now once-daily Xeljanz XR may simplify dosing over Xeljanz BID.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote